| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Amie Y Lee | |
| Biao He | |||
| David M Jablons | |||
| Dan J Raz | |||
| P2860 | cites work | The European mesothelioma epidemic | Q24650064 |
| Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters | Q24676844 | ||
| Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression | Q47814346 | ||
| Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. | Q53632285 | ||
| Cadherins, catenins and APC in pleural malignant mesothelioma | Q54516140 | ||
| EGFR overexpression in malignant pleural mesothelioma | Q61698043 | ||
| The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions | Q63547911 | ||
| Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium | Q72117372 | ||
| Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres | Q73336080 | ||
| The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma | Q74185593 | ||
| Alterations of the p16(INK4) locus in human malignant mesothelial tumors | Q74461537 | ||
| Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma | Q78081432 | ||
| Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression | Q78140641 | ||
| EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma | Q79268942 | ||
| The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities | Q81382355 | ||
| Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma | Q81519769 | ||
| P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma | Q81707933 | ||
| The INK4a/ARF network in tumour suppression | Q28190064 | ||
| Tumor suppression by Ink4a-Arf: progress and puzzles | Q28207959 | ||
| Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops | Q28210619 | ||
| Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma | Q28268844 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product | Q33183808 | ||
| The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. | Q33389811 | ||
| Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma | Q33680576 | ||
| SV40 and human tumours: myth, association or causality? | Q34161997 | ||
| Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma | Q34214330 | ||
| Review of epidermal growth factor receptor biology | Q34320636 | ||
| Wnt2 as a new therapeutic target in malignant pleural mesothelioma | Q34419678 | ||
| Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma | Q34499542 | ||
| A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells | Q34787867 | ||
| Asbestos and the pleura: a review | Q35684938 | ||
| Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments | Q35780958 | ||
| Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development | Q35789268 | ||
| Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma | Q35839893 | ||
| Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody | Q35982617 | ||
| Persistent induction of c-fos and c-jun expression by asbestos | Q36236354 | ||
| VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. | Q36641154 | ||
| Expression of bcl-2 family members in malignant pleural mesothelioma | Q38437441 | ||
| The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas | Q38474132 | ||
| Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma | Q38479413 | ||
| A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent | Q40208072 | ||
| Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells | Q40253864 | ||
| Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas | Q40287001 | ||
| Inactivation of p16INK4a expression in malignant mesothelioma by methylation | Q40694393 | ||
| Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen | Q40735845 | ||
| The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor | Q40755750 | ||
| Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells | Q41731114 | ||
| Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. | Q42442790 | ||
| Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma | Q43558001 | ||
| Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma | Q43747147 | ||
| Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma | Q43802258 | ||
| Simian virus-40 large-T antigen binds p53 in human mesotheliomas. | Q45761189 | ||
| Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus | Q45873541 | ||
| Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines | Q45873629 | ||
| Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. | Q46402560 | ||
| The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro | Q46469316 | ||
| Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. | Q46625222 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular biology | Q7202 |
| P304 | page(s) | 1454-1461 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Update on the molecular biology of malignant mesothelioma | |
| P478 | volume | 109 |
| Q39707042 | 3-O-Methylfunicone, a metabolite produced by Penicillium pinophilum, modulates ERK1/2 activity, affecting cell motility of human mesothelioma cells. |
| Q47425620 | 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma. |
| Q35855798 | A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. |
| Q41846143 | A potential therapeutic strategy for malignant mesothelioma with gene medicine |
| Q54409505 | A3 Receptors Are Overexpressed in Pleura from Patients with Mesothelioma and Reduce Cell Growth via Akt/Nuclear Factor-κB Pathway |
| Q37692445 | Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma |
| Q37287506 | Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma. |
| Q60928995 | Biodistribution and Tumor Uptake of Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft |
| Q39528131 | Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin |
| Q53879306 | Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM). |
| Q36074154 | Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma |
| Q59033566 | Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins |
| Q36503271 | Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma. |
| Q40003684 | Expression of cell adhesion molecule 1 in malignant pleural mesothelioma as a cause of efficient adhesion and growth on mesothelium. |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q38079969 | Gene therapy for malignant mesothelioma: current prospects and challenges |
| Q33862523 | HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts |
| Q55311618 | Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity. |
| Q34974037 | Interferon-β produces synergistic combinatory anti-tumor effects with cisplatin or pemetrexed on mesothelioma cells |
| Q42073845 | Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients |
| Q33691348 | Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors |
| Q31019143 | MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data |
| Q34080881 | Malignant pleural and peritoneal mesothelioma consequential to brief indirect asbestos exposure |
| Q36361245 | Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways |
| Q38012566 | Molecular pathogenesis of malignant mesothelioma |
| Q34795828 | Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma |
| Q52581757 | New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. |
| Q39501588 | New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization |
| Q36354021 | Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells |
| Q34360248 | Overview of the biochemical and genetic processes in malignant mesothelioma. |
| Q36828498 | Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors |
| Q81958277 | Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors |
| Q34589641 | Peritoneal mesothelioma in a woman who has survived for seven years: a case report |
| Q39841354 | Placenta growth factor is a survival factor for human malignant mesothelioma cells |
| Q33390251 | Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas |
| Q92591513 | Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy |
| Q37290519 | Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. |
| Q33874196 | The investigation of effects of quercetin and its combination with Cisplatin on malignant mesothelioma cells in vitro |
| Q38176008 | The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors |
| Q53193985 | Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. |
| Q80426618 | [Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic] |
| Q39431961 | β-catenin expression in benign and malignant pleural disorders. |
Search more.